• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Successful rescue treatment of sepsis due to a pandrug-resistant, NDM-producing Klebsiella pneumoniae using aztreonam powder for nebulizer solution as intravenous therapy in combination with ceftazidime/avibactam.使用雾化用氨曲南粉作为静脉治疗药物联合头孢他啶/阿维巴坦成功救治产新德里金属β-内酰胺酶（NDM）的泛耐药肺炎克雷伯菌所致败血症
J Antimicrob Chemother. 2020 Mar 1;75(3):773-775. doi: 10.1093/jac/dkz495.
2
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .头孢他啶-阿维巴坦对产碳青霉烯酶的. 的体外和体内杀菌活性。
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.
3
Successful Treatment of NDM Sepsis and Intestinal Decolonization with Ceftazidime/Avibactam Plus Aztreonam Combination in a Patient with TTP Complicated by SARSCoV-2 Nosocomial Infection.头孢他啶/阿维巴坦联合氨曲南成功治疗血栓性血小板减少性紫癜合并新型冠状病毒医院感染患者的NDM败血症及肠道去定植
Medicina (Kaunas). 2021 Apr 28;57(5):424. doi: 10.3390/medicina57050424.
4
Aztreonam plus ceftazidime-avibactam as treatment of NDM-1-producing Klebsiella pneumoniae bacteraemia in a neutropenic patient: Last resort therapy?替加环素联合头孢他啶-阿维巴坦治疗中性粒细胞减少症患者产 NDM-1 肺炎克雷伯菌菌血症：最后的治疗手段？
J Glob Antimicrob Resist. 2020 Dec;23:417-419. doi: 10.1016/j.jgar.2020.10.019. Epub 2020 Nov 16.
5
Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1.监测头孢他啶-阿维巴坦和氨曲南在治疗一株携带肺炎克雷伯菌碳青霉烯酶 4 型和新德里金属β-内酰胺酶 1 型的多药耐药肠杆菌引起的血流感染中的浓度。
Clin Infect Dis. 2020 Aug 14;71(4):1095-1098. doi: 10.1093/cid/ciz1155.
6
Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies.肺炎克雷伯菌对依拉环素耐药的产生及协同治疗策略的伴随敏感性指导设计。
Microbiol Spectr. 2022 Oct 26;10(5):e0139022. doi: 10.1128/spectrum.01390-22. Epub 2022 Aug 16.
7
Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection.头孢他啶/阿维巴坦与氨曲南联合治疗产NDM-1/OXA-48/CTX-M-15肺炎克雷伯菌感染后的临床结局
J Antimicrob Chemother. 2018 Apr 1;73(4):1104-1106. doi: 10.1093/jac/dkx496.
8
Will ceftazidime/avibactam plus aztreonam be effective for NDM and OXA-48-Like producing organisms: Lessons learnt from study.头孢他啶/阿维巴坦联合氨曲南对产NDM和OXA-48样酶的微生物是否有效：研究所得经验教训
Indian J Med Microbiol. 2019 Jan-Mar;37(1):34-41. doi: 10.4103/ijmm.IJMM_19_189.
9
Outcomes of 23 patients diagnosed with New Delhi metallo-beta-lactamase (NDM)-producing Klebsiella pneumoniae infection treated with ceftazidime/avibactam and aztreonam at a single center in Poland.波兰一家单中心对 23 例产新德里金属β-内酰胺酶（NDM）肺炎克雷伯菌感染患者使用头孢他啶/阿维巴坦和氨曲南治疗的结果。
Eur J Clin Microbiol Infect Dis. 2024 Aug;43(8):1579-1587. doi: 10.1007/s10096-024-04859-y. Epub 2024 May 29.
10
Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane Integrity.针对产 NDM-和 CTX-M 型肺炎克雷伯菌的细胞壁合成和外膜完整性的靶向治疗机制研究。
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0052722. doi: 10.1128/aac.00527-22. Epub 2022 Aug 4.

引用本文的文献

1
Aztreonam-avibactam: The dynamic duo against multidrug-resistant gram-negative pathogens.阿曲南-阿维巴坦：对抗多重耐药革兰氏阴性病原体的活力组合。
Pharmacotherapy. 2024 Dec;44(12):927-938. doi: 10.1002/phar.4629. Epub 2024 Nov 27.
2
Phenotypic and Genotypic Characterization of Pan-Drug-Resistant Isolated in Qatar.卡塔尔分离出的泛耐药菌的表型和基因型特征
Antibiotics (Basel). 2024 Mar 19;13(3):275. doi: 10.3390/antibiotics13030275.
3
Screening of MMV pandemic response and pathogen box compounds against pan-drug-resistant to identify potent inhibitory compounds.筛选MMV大流行应对药物和病原体盒式化合物以对抗泛耐药性，从而鉴定出有效的抑制性化合物。
New Microbes New Infect. 2023 Nov 7;55:101193. doi: 10.1016/j.nmni.2023.101193. eCollection 2023 Oct.
4
Current and Emerging Treatment Options for Multidrug Resistant Urosepsis: A Review.多重耐药性泌尿道感染的当前及新出现的治疗选择：综述
Antibiotics (Basel). 2022 Dec 15;11(12):1821. doi: 10.3390/antibiotics11121821.
5
Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections.头孢他啶-阿维巴坦在多重耐药革兰氏阴性菌感染中的临床应用更新。
Infection. 2022 Dec;50(6):1409-1423. doi: 10.1007/s15010-022-01876-x. Epub 2022 Jul 4.
6
β-Lactam Antibiotics and β-Lactamase Enzymes Inhibitors, Part 2: Our Limited Resources.β-内酰胺类抗生素与β-内酰胺酶抑制剂，第二部分：我们有限的资源
Pharmaceuticals (Basel). 2022 Apr 13;15(4):476. doi: 10.3390/ph15040476.
7
Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).美国传染病学会 2022 年关于治疗产超广谱β-内酰胺酶肠杆菌科细菌（ESBL-E）、耐碳青霉烯肠杆菌科细菌（CRE）和治疗困难的耐药铜绿假单胞菌（DTR-P. aeruginosa）的指导意见。
Clin Infect Dis. 2022 Aug 25;75(2):187-212. doi: 10.1093/cid/ciac268.
8
Differences in the Distribution of Species, Carbapenemases, Sequence Types, Antimicrobial Heteroresistance and Mortality Rates Between Pediatric and Adult Carbapenemase-Producing in Bloodstream Infections.血流感染中产碳青霉烯酶的儿童与成人患者在菌种分布、碳青霉烯酶类型、序列类型、抗菌药物异质性耐药及死亡率方面的差异
Front Med (Lausanne). 2022 Mar 14;9:827474. doi: 10.3389/fmed.2022.827474. eCollection 2022.
9
Recommendations for antibiotic selection for severe nosocomial infections.严重医院获得性感染的抗生素选择建议。
Rev Esp Quimioter. 2021 Oct;34(5):511-524. doi: 10.37201/req/126.2021. Epub 2021 Oct 25.
10
The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases.氨曲南与阿维巴坦联合用于治疗产金属β-内酰胺酶革兰阴性菌的研究进展：体外研究与临床病例的系统评价
Antibiotics (Basel). 2021 Aug 20;10(8):1012. doi: 10.3390/antibiotics10081012.

本文引用的文献

1
Successful Treatment of Bacteremia Due to NDM-1-Producing with Aztreonam and Ceftazidime-Avibactam Combination in a Pediatric Patient with Hematologic Malignancy.在一名患有血液系统恶性肿瘤的儿科患者中，使用氨曲南和头孢他啶-阿维巴坦联合治疗成功治愈了由产NDM-1菌株引起的菌血症。
Antimicrob Agents Chemother. 2019 Jan 29;63(2). doi: 10.1128/AAC.02463-18. Print 2019 Feb.
2
Genomic Analysis of a Pan-Resistant Isolate of , United States 2016.2016 年美国泛耐药分离株 的基因组分析。
mBio. 2018 Apr 3;9(2):e00440-18. doi: 10.1128/mBio.00440-18.
3
Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.产超广谱β-内酰胺酶、AmpC 酶和碳青霉烯酶肠杆菌科细菌感染的治疗。
Clin Microbiol Rev. 2018 Feb 14;31(2). doi: 10.1128/CMR.00079-17. Print 2018 Apr.
4
Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection.头孢他啶/阿维巴坦与氨曲南联合治疗产NDM-1/OXA-48/CTX-M-15肺炎克雷伯菌感染后的临床结局
J Antimicrob Chemother. 2018 Apr 1;73(4):1104-1106. doi: 10.1093/jac/dkx496.
5
Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae.单独使用头孢他啶/阿维巴坦或与氨曲南联合使用治疗对黏菌素耐药且产碳青霉烯酶的肺炎克雷伯菌。
J Antimicrob Chemother. 2018 Feb 1;73(2):542-544. doi: 10.1093/jac/dkx393.
6
Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy To Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa.头孢他啶-阿维巴坦与氨曲南：克服肠杆菌科细菌和铜绿假单胞菌中金属β-内酰胺酶介导的β-内酰胺耐药性的有趣策略
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.01008-17. Print 2017 Sep.
7
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?头孢他啶-阿维巴坦和氨曲南能否克服肠杆菌科细菌中金属β-内酰胺酶介导的β-内酰胺耐药性？
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02243-16. Print 2017 Apr.

Successful rescue treatment of sepsis due to a pandrug-resistant, NDM-producing Klebsiella pneumoniae using aztreonam powder for nebulizer solution as intravenous therapy in combination with ceftazidime/avibactam.

作者信息

Sieswerda Elske, van den Brand Marre, van den Berg Roland B, Sträter Joris, Schouls Leo, van Dijk Karin, Budding Andries E

机构信息

Department of Medical Microbiology and Infection Control, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Department of Medical Microbiology, Meander Medical Centre, Amersfoort, The Netherlands.

出版信息

J Antimicrob Chemother. 2020 Mar 1;75(3):773-775. doi: 10.1093/jac/dkz495.

DOI:10.1093/jac/dkz495
PMID:31789378
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7021014/
Abstract
摘要